Oculis (NASDAQ:OCS) Releases Earnings Results, Misses Estimates By $0.28 EPS

Oculis (NASDAQ:OCS) posted its quarterly earnings data on Tuesday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Oculis Price Performance

Shares of OCS traded down $0.10 during mid-day trading on Thursday, reaching $18.74. The company had a trading volume of 20,754 shares, compared to its average volume of 84,855. The company has a market capitalization of $759.00 million, a price-to-earnings ratio of -9.71 and a beta of 0.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company’s 50 day simple moving average is $20.86 and its 200 day simple moving average is $16.88. Oculis has a 1-year low of $10.55 and a 1-year high of $23.08.

Analysts Set New Price Targets

Several equities analysts have recently commented on OCS shares. HC Wainwright dropped their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research report on Thursday. Finally, Robert W. Baird raised their target price on Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.